+123.2%
TEAM vs MRNA
+521.0%
-397.8%
-87.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +0.7% | +0.3% | +1.0% |
| 7D | -7.8% | -8.2% | +0.5% | -7.0% |
| 30D | +16.5% | +125.6% | -109.0% | -0.8% |
| 3M | +96.2% | +197.1% | -100.9% | +60.2% |
| 6M | +130.2% | +148.5% | -18.3% | +91.8% |
| YTD | +10.7% | +363.3% | -352.5% | -16.7% |
| 1Y | +3.0% | +462.0% | -459.0% | -25.5% |
| 3Y | -13.1% | +26.9% | -40.0% | -25.5% |
| 5Y | -52.7% | -69.6% | +16.9% | -55.3% |
| All | +123.2% | +521.0% | -397.8% | +72.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling